As of Mar 27
| +0.94 / +0.22%|
The 20 analysts offering 12-month price forecasts for Biogen have a median target of 499.00, with a high estimate of 554.00 and a low estimate of 350.00. The median estimate represents a +16.08% increase from the last price of 429.87.
The current consensus among 27 polled investment analysts is to Buy stock in Biogen. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.